{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-030267","form_type":"8-K","ticker":"MIST","cik":"0001408443","company_name":"Milestone Pharmaceuticals Inc.","filed_at":"2024-03-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.086351+00:00","generated_at":"2026-06-05T04:38:58.299930+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Milestone Pharmaceuticals prices $30M public offering; net proceeds ~$32.4M","bullets":["Offering of 16,666,667 common shares at $1.50/share and 3,333,333 pre-funded warrants at $1.499/warrant.","Underwriters' option for 3,000,000 additional common shares exercised in full.","Net proceeds of ~$32.4M to fund etripamil development for PSVT and AFib-RVR, plus working capital.","Expected to close on or about March 4, 2024, subject to customary conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-030267","json":"https://secwatch.observer/filing/0001104659-24-030267.json","markdown":"https://secwatch.observer/filing/0001104659-24-030267.md","text":"https://secwatch.observer/filing/0001104659-24-030267.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1408443/000110465924030267/0001104659-24-030267-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1408443/000110465924030267/tm247820d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T04:38:58.299930+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"40e4e8b49673146abfc6f55b8b17df234e2fd0c7","claim":"Milestone Pharmaceuticals Inc. entered into Underwriting Agreement with Piper Sandler & Co. as representative of the several underwriters (effective 2024-02-28).","evidence_excerpt":"On February 28, 2024, Milestone Pharmaceuticals Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Piper Sandler & Co. as representative of the several underwriters listed on Schedule A thereto (the “Underwriters”), related to an underwritten public offering (the “Offering”) of 16,666,667 of the Company’s common shares, without par value (the “Common Shares”), at a public offering price of $1.50 per share","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465924030267/0001104659-24-030267-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"underwriting"},{"label":"Counterparty","value":"Piper Sandler & Co. as representative of the several underwriters"},{"label":"Effective","value":"2024-02-28"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}